[Biomarker for colorectal cancer].

Takeshi Nagasaka, Yoshiko Mori, Yuzo Umeda, Toshiyoshi Fujiwara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Discovery of usable molecular biomarkers is the step closer to a realization of personalized therapy for patients with colorectal cancer(CRC). Herein we present an update of the most recent data on promising biological prognostic and/or predictive markers, including microsatellite instability(MSI) and KRAS/BRAF mutations. Additionally, we propose a new genetic classification for CRC based on MSI and KRAS/BRAF mutation status (a 2 x 3 matrix). The 2 x 3 matrix is constructed of 6 cells that are made by [MSI/non-MSI] x [BRAF mutant/KRAS mutant/wild type of the both genes]. All of CRC including Lynch syndrome could be classified without overlapping into the 6 cells. More interestingly, each cell has each promising biological prognostic and/or predictive feature, which will help clinicians to make personalized treatment strategy for each CRC patient.

Original languageEnglish
Pages (from-to)802-808
Number of pages7
JournalNihon rinsho. Japanese journal of clinical medicine
Volume70
Issue number5
Publication statusPublished - May 2012

Fingerprint

Microsatellite Instability
Colorectal Neoplasms
Biomarkers
Hereditary Nonpolyposis Colorectal Neoplasms
Mutation
Therapeutics
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[Biomarker for colorectal cancer]. / Nagasaka, Takeshi; Mori, Yoshiko; Umeda, Yuzo; Fujiwara, Toshiyoshi.

In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 70, No. 5, 05.2012, p. 802-808.

Research output: Contribution to journalArticle

@article{fa858d5b7f94423e8a35537adbdb4df0,
title = "[Biomarker for colorectal cancer].",
abstract = "Discovery of usable molecular biomarkers is the step closer to a realization of personalized therapy for patients with colorectal cancer(CRC). Herein we present an update of the most recent data on promising biological prognostic and/or predictive markers, including microsatellite instability(MSI) and KRAS/BRAF mutations. Additionally, we propose a new genetic classification for CRC based on MSI and KRAS/BRAF mutation status (a 2 x 3 matrix). The 2 x 3 matrix is constructed of 6 cells that are made by [MSI/non-MSI] x [BRAF mutant/KRAS mutant/wild type of the both genes]. All of CRC including Lynch syndrome could be classified without overlapping into the 6 cells. More interestingly, each cell has each promising biological prognostic and/or predictive feature, which will help clinicians to make personalized treatment strategy for each CRC patient.",
author = "Takeshi Nagasaka and Yoshiko Mori and Yuzo Umeda and Toshiyoshi Fujiwara",
year = "2012",
month = "5",
language = "English",
volume = "70",
pages = "802--808",
journal = "Nippon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "5",

}

TY - JOUR

T1 - [Biomarker for colorectal cancer].

AU - Nagasaka, Takeshi

AU - Mori, Yoshiko

AU - Umeda, Yuzo

AU - Fujiwara, Toshiyoshi

PY - 2012/5

Y1 - 2012/5

N2 - Discovery of usable molecular biomarkers is the step closer to a realization of personalized therapy for patients with colorectal cancer(CRC). Herein we present an update of the most recent data on promising biological prognostic and/or predictive markers, including microsatellite instability(MSI) and KRAS/BRAF mutations. Additionally, we propose a new genetic classification for CRC based on MSI and KRAS/BRAF mutation status (a 2 x 3 matrix). The 2 x 3 matrix is constructed of 6 cells that are made by [MSI/non-MSI] x [BRAF mutant/KRAS mutant/wild type of the both genes]. All of CRC including Lynch syndrome could be classified without overlapping into the 6 cells. More interestingly, each cell has each promising biological prognostic and/or predictive feature, which will help clinicians to make personalized treatment strategy for each CRC patient.

AB - Discovery of usable molecular biomarkers is the step closer to a realization of personalized therapy for patients with colorectal cancer(CRC). Herein we present an update of the most recent data on promising biological prognostic and/or predictive markers, including microsatellite instability(MSI) and KRAS/BRAF mutations. Additionally, we propose a new genetic classification for CRC based on MSI and KRAS/BRAF mutation status (a 2 x 3 matrix). The 2 x 3 matrix is constructed of 6 cells that are made by [MSI/non-MSI] x [BRAF mutant/KRAS mutant/wild type of the both genes]. All of CRC including Lynch syndrome could be classified without overlapping into the 6 cells. More interestingly, each cell has each promising biological prognostic and/or predictive feature, which will help clinicians to make personalized treatment strategy for each CRC patient.

UR - http://www.scopus.com/inward/record.url?scp=84864496537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864496537&partnerID=8YFLogxK

M3 - Article

C2 - 22620004

AN - SCOPUS:84864496537

VL - 70

SP - 802

EP - 808

JO - Nippon rinsho. Japanese journal of clinical medicine

JF - Nippon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 5

ER -